LTGO Company Profile and Key Details

Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $36.00. The high target offers 117.01% upside. The low target suggests 56.25% downside. The mean target is $43.00. This offers 86.63% upside. Latigo Biotherapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended September 03, 2026, missed forecasts by 4.51%. The prior quarter beat by 234.59%. Over the last six quarters, Apple has recorded several small beats. These include 234.59% in July 17, 2026.

Average 10-day trading volume of 206.46 thousand shares is in line with the 3-month average of 226.51 thousand, indicating normal recent market interest.

Our AI price prediction model suggests that Latigo Biotherapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.56%, with price expected at $21.99 by September 18, 2026, within a range of $20.90 to $23.03 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 03, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 03, 2027, within a range of $0.00 to $0.00.

Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $43.00, suggesting 86.63% upside. Our AI forecast model points to short-term weakness (-4.56% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Latigo Biotherapeutics Inc. (NASDAQ:LTGO) closed at $23.04 USD, gaining $0.56 (2.49%) from the previous close of $22.48. The stock is currently mid-range between its 52-week high and low $17.22 and $25.93. With a market capitalization of about $1.39 billion, Latigo Biotherapeutics Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 380.40 thousand shares, volume is running light vs its 52-week average. Headquartered in Thousand Oak, CA, Latigo Biotherapeutics Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Nima Farzan, the company employs approximately 59 people and listed since August 07, 2026. Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction.